BBIO:NSD-BridgeBio Pharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 65.79

Change

-3.69 (-5.31)%

Market Cap

USD 8.53B

Volume

2.42M

Average Target Price

USD 63.38 (-3.67%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California. Address: 421 Kipling Street, Palo Alto, CA, United States, 94301

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

USD21.44B 47.64 35.20

ETFs Containing BBIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.48% 7% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.48% 7% F 6% F
Trailing 12 Months  
Capital Gain 89.05% 71% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.05% 71% C- 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.62% 59% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.62% 59% F 73% C
Risk Return Profile  
Volatility (Standard Deviation) 35.13% 75% C 40% F
Risk Adjusted Return 53.01% 80% B- 73% C
Market Capitalization 8.53B 95% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 51.41 3% F 3% F
Price / Cash Flow Ratio -33.62 82% B- 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -122.43% 22% F 9% F
Return on Invested Capital -136.27% 15% F 6% F
Return on Assets -37.25% 32% F 9% F
Debt to Equity Ratio 22.47% 46% F 62% D-
Technical Ratios  
Short Ratio 16.25 3% F 2% F
Short Percent 20.97% 7% F 9% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector